← Back to Clinical Trials
Recruiting NCT06289517
PET Imaging of 68Ga-Her2-affibody in Tumors with High Her2 Expression
Trial Parameters
Condition Neoplasms
Sponsor Peking University First Hospital
Study Type INTERVENTIONAL
Phase N/A
Enrollment 30
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-05-28
Completion 2025-07-30
Interventions
68Ga-Her2-affibody
Brief Summary
This project uses HER2 protein as the target group of radiodrugs to explore the diagnostic efficacy, safety and metabolic characteristics of 68Ga-Her2-affibody in the expression status of HER2, aiming to provide a new imaging method for the determination of HER2 status in breast cancer At the same time, it also provides new methods and means for early diagnosis, accurate staging, recurrence judgment, treatment decision-making and prognosis judgment of malignant tumors such as lung cancer, gastrointestinal cancer and bladder cancer, and provides scientific basis for precise treatment of malignant tumors.
Eligibility Criteria
Inclusion Criteria: \- patients with confirmed or suspected cancer; Signed written informed consent Exclusion Criteria: \-